From April 17 to 21, the ESCMID Global Congress, one of the world’s leading events in clinical microbiology and infectious diseases, was held in Munich, Germany, bringing together global experts, researchers, and industry leaders to explore advances in diagnostics and treatment.
Wondfo presented its microfluidics-based molecular POCT solution, the U-CardDx 200. Leveraging magnetic bead-based nucleic acid extraction and real-time qPCR, the system delivers results in just 15 minutes, attracting strong interest from international attendees and highlighting Wondfo’s advancements in molecular diagnostics.

 

Advancing the Standard for Molecular POCT

Magnetic bead-based nucleic acid extraction combined with real-time qPCR is widely recognized as a gold-standard methodology in molecular diagnostics, offering high sensitivity and specificity for clinical applications.

With years of R&D, Wondfo has addressed key technical challenges, including sample preprocessing, system miniaturization, fluid control, and rapid thermal cycling.

The system is the first of its kind developed in China to complete a full nucleic acid testing workflow within 15 minutes, achieving a sensitivity of 200 copies/mL—setting a new benchmark for molecular POCT.

Strong Global Engagement Highlights Market Recognition

Wondfo’s booth attracted visitors worldwide, who explored the system’s performance and application scenarios while recognizing its combination of rapid turnaround time and reliable accuracy.
 
Experts in clinical microbiology and infectious diseases highlighted the system’s intuitive design and ease of use. Its 15-minute turnaround time was seen as a meaningful advancement in addressing long-standing challenges in rapid clinical diagnostics.

 

Strategic Partnerships Strengthen Global Expansion

During ESCMID, Wondfo entered into strategic cooperation agreements with partners across Europe, the Middle East, and other regions, further strengthening its position in the global molecular diagnostics market.
 
This congress marks a further step in Wondfo’s global expansion. By focusing on unmet clinical needs, Wondfo continues to advance technology and optimize its product portfolio to deliver more efficient, accurate, and accessible diagnostic solutions worldwide.

 

Wondfo will continue advancing molecular diagnostics through innovation and global collaboration, accelerating access to high-quality diagnostic solutions. Committed to speed and precision, Wondfo supports timely diagnosis and improved patient outcomes.